morphine
Enable an AI agent to recognise material represented as morphine, assess its documented identity and usable state, and determine which handling or use decisions require further evidence or authority.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
Researched by: Codex + Grok
Purpose and description
Enable an AI agent to recognise material represented as morphine, assess its documented identity and usable state, and determine which handling or use decisions require further evidence or authority.
Morphine is the principal morphinan alkaloid of opium latex from Papaver somniferum and a prototypical μ-opioid receptor agonist used as the reference strong opioid analgesic and chemical parent of many semi-synthetic opioids.
It can be Compare identity evidence with a morphine-specific reference and flag unresolved distinctions.; Interpret and compare reported content only when chemical form and quantity basis are explicit.; Link analytical results and provenance to the particular lot or sampled portion they support.; Flag condition changes, storage excursions or evidence gaps for qualified assessment.; Determine whether a proposed handling, transfer or use action has sufficient evidence and applicable authority.; Record quarantine, release or disposal decisions with their purpose, responsible authority and supporting evidence..
Distinguishing features
Require identity evidence that distinguishes morphine from related substances such as codeine and diamorphine; an opioid designation alone does not establish morphine identity.
Separate the morphine chemical entity from its named salt or hydrate form and from a formulated medicine containing it.
Check whether a reported quantity describes morphine on a stated equivalent basis, a particular salt form, or the total mass of a preparation.
Distinguish a specimen shown to contain morphine from material whose identity and specification are established as morphine.
Treat a label, supplier claim or screening result as a stated level of evidence rather than automatically as confirmed identity.
Scope
+ Evidence establishing morphine identity and distinguishing related substances
+ Chemical form and the basis on which morphine content is expressed
+ Morphine content, relevant impurities and uncertainty in analytical results
+ Material condition, storage history and suitability for an explicitly stated purpose
+ Provenance and applicable restrictions on possession, transfer, handling and use
- Patient diagnosis, prescribing, dose selection and treatment monitoring
- Complete medicinal-product specifications, delivery devices and packaging designs
- Manufacturing or extraction procedures and process optimisation
- Complete models of related opioids, metabolites and degradation products
- Laboratory instrument operation and analytical-method implementation
- Jurisdiction-wide controlled-substance legislation and licensing systems
Characteristics
- Morphine identity status
- claimed | provisionally supported | confirmed for stated purpose | contradicted | unresolved Determines whether downstream decisions can rely on the material being morphine.
- Chemical form
- free base or identified salt; hydration or solvation state where established; unknown Prevents different material forms from being treated as interchangeable without supporting evidence.
- Material context
- bulk substance | reference material | medicinal preparation | mixture | specimen containing morphine | unknown Separates substance identity from the requirements of the material in which it occurs.
- Measured morphine content
- mass fraction, mg/g, mg/mL or amount per unit, with explicit chemical basis, method and uncertainty Allows quantities to be interpreted without confusing salt mass, morphine-equivalent content and preparation mass.
- Related-substance profile
- identified analytes and measured amounts or fractions, including reporting limits and unresolved signals Supports assessment of identity, contamination and change during storage.
- Physical condition
- observed appearance and physical state, compared with the applicable material specification Records changes that may require investigation without treating appearance as proof of identity or acceptability.
- Storage exposure
- recorded temperature, humidity and light exposure where relevant, with duration and gaps Supports a form-specific assessment of whether storage history compromises suitability.
- Lot and evidence linkage
- links to source, lot, sampled portion, analytical records and custody events Establishes which physical material a certificate or result actually describes.
- Suitability disposition
- unassessed | acceptable for named purpose | restricted | quarantined | rejected Avoids treating identity confirmation as permission for every possible use.
- Applicable authority
- current jurisdiction, responsible actor, permitted activity and supporting authority Makes possession, transfer and use decisions dependent on the relevant legal and institutional context.
Where this came from
wikidata · CC0 1.0
Also registered as vr.tr.morphine
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 18 findings · 28 questions.
Morphine identity Establishes what the material is and how strongly its identification is supported.
An opioid label, a morphine-containing specimen and an identified morphine substance support different decisions.
Chemical entity
Defines the entity represented by the registry entry and its nearby boundaries.
Entity and form boundary
Record whether the identification denotes morphine itself, a specified chemical form or a preparation containing it.
- Which authoritative chemical identity, including stereochemical identity where relevant, anchors the name morphine? definition
- Does this material represent morphine, a morphine salt or hydrate, or a preparation or specimen containing morphine? boundary
Identity evidence
Connects identity claims to evidence capable of resolving relevant alternatives.
Discriminating identification
Record the evidential strength and limitations of the identification.
- What examined evidence supports morphine identity for this lot or sampled portion? provenance
- Which plausible alternatives, including codeine, diamorphine or mixed material, does that evidence distinguish or leave unresolved? boundary
Form and content Makes morphine quantities interpretable across chemical forms and material contexts.
A quantity labelled morphine is ambiguous unless its chemical basis and preparation context are known.
Chemical form
Records the form associated with the measured or labelled material.
Salt and hydration basis
Make the stated free-base, salt and hydration or solvation basis explicit without inferring it from a shortened name.
- What chemical form is stated, and what evidence establishes its counterion and hydration or solvation state where applicable? definition
- Does the content declaration use that form's mass or a specified morphine-equivalent basis? measurement
Content expression
Distinguishes measured substance content from total preparation quantity.
Assay and quantity interpretation
Record content with the denominator, chemical basis and limitations needed to interpret it.
- What morphine content was measured, in which units and matrix, using which method and uncertainty or reporting limits? measurement
- Can two reported quantities be compared directly, or is a documented chemical-form conversion or product-level interpretation required? boundary
Purity and condition Assesses whether the morphine material remains consistent with a stated specification and purpose.
Morphine identity alone does not establish purity, stability or suitability.
Related substances
Records relevant non-morphine constituents and the evidence for their significance.
Impurity profile
Separate identified impurities, possible degradation products and unresolved analytical signals.
- Which related substances or contaminants were examined, detected or left unresolved, and at what reporting limits? measurement
- Which applicable specification establishes whether these results are acceptable for this chemical form and intended purpose? provenance
Stability and storage
Relates observed condition and exposure history to evidence applicable to the actual form or preparation.
Condition change assessment
Record changes and storage deviations without inventing a universal morphine shelf life.
- What physical or analytical changes and storage excursions have been recorded since the relevant baseline assessment? measurement
- What form-specific or product-specific evidence supports continued use, retesting or quarantine after those changes? action
Provenance and control Connects morphine material to its evidence, custody and applicable permissions.
An agent must establish both which material its evidence describes and whether a proposed activity is authorised.
Lot provenance
Maintains the connection between source material, samples and supporting records.
Evidence-to-material link
Record whether identity and quality documents apply to the material currently under consideration.
- How are the current container or portion, originating lot and examined sample linked to the identity and assay records? provenance
- Which transfers, repackaging events or custody gaps limit reliance on those records? provenance
Activity authority
Resolves permissions for the particular actor, location, material and proposed activity.
Permitted morphine activity
Reference current legal and institutional authority rather than embedding a universal permission rule.
- Which current jurisdictional and institutional requirements apply to this morphine material and proposed activity? boundary
- What evidence establishes that the responsible actor may possess, transfer, use or dispose of it in this context? action
Purpose and disposition Connects evidence about morphine to a bounded decision about its next permitted use.
Acceptance for analytical work, pharmaceutical manufacture and administration requires different evidence and neighbouring models.
Intended-use boundary
States the purpose against which material suitability is being assessed.
Purpose-specific suitability
Prevent a general identity or purity result from becoming an unsupported claim of clinical usability.
- For which explicit purpose is this morphine material being assessed, and what acceptance requirements follow? definition
- Which decisions require a medicinal-product, patient-care or other neighbouring model before use can proceed? boundary
Handling and disposition
Records justified next actions and unresolved conditions preventing them.
Evidence-supported next action
Tie release, restriction, quarantine or disposal to morphine-specific evidence and responsible authority.
- Which handling requirements apply to the actual morphine form and concentration, and what authoritative material-specific guidance supports them? action
- Given the identity, content, condition and authority evidence, what disposition is justified and which unresolved issues prevent the proposed action? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Kinds and varieties
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- morphine free base
- morphine sulfate (anhydrous and pentahydrate)
- morphine hydrochloride (anhydrous and trihydrate)
- morphine tartrate
- immediate-release oral morphine
- extended-release oral morphine
- parenteral morphine (IV, IM, SC)
- neuraxial morphine (epidural or intrathecal)
- Which of these kinds and varieties hold for the sense of morphine this model covers, and on what evidence? provenance
Identifiers and schemes
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Wikidata - Q81225 - Item for the chemical compound morphine.
- CAS Registry Number - 57-27-2 - Free base.
- CAS Registry Number - 64-31-3 - Morphine sulfate, anhydrous (2:1).
- CAS Registry Number - 6211-15-0 - Morphine sulfate pentahydrate, the usual pharmaceutical sulfate.
- CAS Registry Number - 52-26-6 - Morphine hydrochloride, anhydrous.
- CAS Registry Number - 6055-06-7 - Morphine hydrochloride trihydrate, common European injectable salt.
- UNII - 76I7G6D29C - FDA Global Substance Registration System identifier for morphine.
- PubChem CID - 5288826 - NCBI PubChem compound record.
- ATC - N02AA01 - WHO Anatomical Therapeutic Chemical code, natural opium alkaloids.
- INN - morphine - WHO International Nonproprietary Name; BAN morphine; DCIT morfina; Latin morphinum.
- DrugBank - DB00295 - DrugBank accession.
- ChEBI - CHEBI:17303 - Chemical Entities of Biological Interest.
- EC number - 200-320-2 - ECHA European Community number.
- INCB IDS - NM 009 - International Narcotics Control Board drug-system code on the Yellow List.
- IUPHAR/BPS - 1627 - Guide to Pharmacology ligand identifier.
- InChIKey - BQJCRHHNABKAKU-KBQPJGBKSA-N - Stereospecific key for the natural (−)-enantiomer.
- Which of these identifiers and schemes hold for the sense of morphine this model covers, and on what evidence? provenance
Standards and regulation
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Single Convention on Narcotic Drugs, 1961, as amended 1972 - United Nations: morphine in Schedule I; some dilute preparations may fall under Schedule III.
- INCB Yellow List of narcotic drugs under international control - International Narcotics Control Board.
- WHO Model List of Essential Medicines (core EML and EMLc), first listed 1977 - World Health Organization.
- WHO ATC/DDD index, N02AA01 - WHO Collaborating Centre for Drug Statistics Methodology.
- United States Controlled Substances Act Schedule II (selected low-dose combinations Schedule III) - DEA/FDA.
- Misuse of Drugs Act 1971 Class A and POM prescription control - United Kingdom.
- Controlled Drugs and Substances Act Schedule I - Canada.
- Standard for the Uniform Scheduling of Medicines and Poisons Schedule 8 - Australia.
- Betäubungsmittelgesetz Anlage III (special prescription form) - Germany.
- Pharmacopoeial monographs: USP Morphine Sulfate; Ph. Eur./BP Morphine hydrochloride and Morphine sulfate; Ph. Int. Morphine Hydrochloride / Morphine Sulfate; JP Morphine Hydrochloride Hydrate - USP, EDQM, MHRA, WHO, PMDA.
- Which of these standards and regulation hold for the sense of morphine this model covers, and on what evidence? provenance
Real-world use
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- First-line strong opioid for severe acute pain (post-operative, trauma, burns) given IV in 2-5 mg titrated increments or IM/SC about 10 mg in opioid-naïve adults.
- WHO step-3 analgesic for cancer and other palliative pain, as oral immediate-release solution or tablets and as 12- or 24-hour modified-release tablets, capsules or granules.
- Neuraxial (epidural or intrathecal) morphine for peri-operative and labour analgesia, at microgram-to-low-milligram doses.
- Reference opioid for morphine milligram equivalent (MME) conversion tables used in chronic-pain prescribing.
- Hospital procedural sedation and, in some services, treatment of neonatal opioid withdrawal.
- Isolation from dried opium-poppy latex (typically about 10% morphine by mass) and as the industrial starting point for codeine, hydromorphone and diacetylmorphine (heroin).
- Illicit injection or oral use of diverted pharmaceutical morphine, and forensic detection of morphine as both a drug of abuse and a heroin metabolite.
- Which of these real-world use hold for the sense of morphine this model covers, and on what evidence? provenance
Typical measurements
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- molecular mass (free base) - 285.34 - g/mol
- oral bioavailability - 20-40 - %
- plasma elimination half-life - 2-3 - h
- duration of analgesia (immediate-release) - 3-7 - h
- equianalgesic adult dose (parenteral vs oral) - 10 parenteral ≈ 30 oral - mg
- typical adult oral immediate-release dose - 10-30 every 4 h - mg
- typical adult IV titration increment - 2-5 - mg
- chronic oral morphine-equivalent caution threshold (CDC/Canada) - 50-90 - mg/day
- morphine content of raw opium - about 10 - % w/w
- aqueous solubility of free base at 20 °C - 149 - mg/L
- protein binding - 30-40 - %
- Which of these typical measurements hold for the sense of morphine this model covers, and on what evidence? provenance
Failure modes and hazards
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Dose-dependent opioid-induced respiratory depression progressing to apnoea, hypoxia and death; risk rises sharply with benzodiazepines, alcohol or high MME.
- Rapid tolerance and physical dependence; abrupt cessation produces a withdrawal syndrome (cramps, lacrimation, sweating, tremor, insomnia).
- Accumulation of the active metabolite morphine-6-glucuronide in renal impairment, prolonging sedation and respiratory depression.
- Histamine release causing pruritus, flushing, bronchospasm and transient hypotension, especially after IV bolus.
- Crushing or chewing extended-release tablets causes dose dumping and overdose.
- Constipation, urinary retention, myoclonus and delirium at high or rapidly escalating doses.
- Diversion, unsafe injection, and infectious complications; pregnancy exposure can cause neonatal opioid withdrawal.
- Incomplete cross-tolerance when rotating to another opioid, so converted doses can be unexpectedly potent.
- Which of these failure modes and hazards hold for the sense of morphine this model covers, and on what evidence? provenance
Regional variation
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- US and USP practice centres on morphine sulfate (often the pentahydrate); much of Europe, the BP, Ph. Eur. and Japan commonly use morphine hydrochloride (often the trihydrate).
- INN/BAN morphine versus German Morphin/Morphium, French morphine, Italian morfina, Latin morphinum; older English morphia is obsolete.
- United Kingdom still uses pharmaceutical diamorphine (heroin) as a hospital alternative to morphine; the United States does not.
- National scheduling labels differ (US Schedule II, UK Class A, Canada Schedule I, Australia S8, Germany Anlage III, Brazil A1) though all implement 1961 Convention Schedule I.
- Medical availability is highly uneven: morphine is on the WHO Essential Medicines List, yet many low- and middle-income countries have very low licit consumption and tight narcotic-import rules.
- Japan lists Morphine Hydrochloride Hydrate as a Japanese Accepted Name; Russian control places morphine and its salts in List II of restricted narcotics.
- Which of these regional variation hold for the sense of morphine this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- codeine (3-methylmorphine) - Codeine is the 3-O-methyl ether and a CYP2D6 prodrug of morphine, roughly one-tenth as potent orally; LC-MS or the free 3-phenol versus 3-methoxy group separates them, and codeine is 1961 Convention Schedule II rather than Schedule I.
- diamorphine / heroin (3,6-diacetylmorphine) - Heroin is the diacetyl ester of morphine; 6-monoacetylmorphine (6-MAM) in blood or urine is the forensic marker of heroin use, whereas morphine alone does not prove heroin.
- hydromorphone - Hydromorphone is 7,8-dihydro-6-ketomorphine, about five to seven times more potent than morphine; distinct chromatographic retention and mass spectrum, not a morphine salt.
- oxycodone - Oxycodone is a 14-hydroxy-3-methoxy-6-keto morphinan, not morphine; oral equianalgesic dose is about 20 mg versus 30 mg morphine, confirmed by specific immunoassay or LC-MS.
- morphine-6-glucuronide - Polar 6-O-glucuronide metabolite that is itself a μ agonist; separated from parent morphine by polarity on LC-MS and accumulates when GFR is low.
- papaveretum / opium alkaloid mixtures - Contain morphine plus other poppy alkaloids (codeine, papaverine, noscapine); a morphine-only assay understates the mixture, and INCB treats such mixtures as morphine preparations when not made directly from opium.
- thebaine - Same morphinan skeleton but a non-analgesic, highly unsaturated poppy alkaloid used to make oxycodone and buprenorphine; distinguished by unsaturation pattern and lack of μ-agonist analgesia.
- fentanyl - A synthetic anilidopiperidine, not a morphinan; immunoassay panels may cross-react poorly, so a morphine-positive result does not identify fentanyl, and vice versa.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of morphine this model covers, and on what evidence? provenance
Sources
- Morphine - Definition, identifiers, legal scheduling, pharmacokinetics, salts, clinical use, and essential-medicine status.
- Morphine | C17H19NO3 | CID 5288826 - CAS, UNII, formula, molecular weight, related salt CAS numbers, and DEA Schedule II status.
- WHO Model List of Essential Medicines: Morphine (section 2.2 Opioid analgesics) - EML/EMLc listing, ATC N02AA01, and authorised oral and parenteral salt formulations.
- Schedules of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol (ST/CND/1/Add.1/Rev.9) - International control of morphine in Schedule I of the 1961 Convention, distinct from codeine in Schedule II.
- Yellow List: List of Narcotic Drugs under International Control - INCB identification of morphine as the principal alkaloid of opium, with CAS 57-27-2 and IDS code NM 009.
- Opioid Analgesics and International Conventions, in WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents - That morphine and other strong opioids are Schedule I narcotics under the 1961 Convention, with medical-use control requirements.
- Morphine (oral route) - Typical oral immediate- and extended-release adult doses and overdose signs (respiratory depression, miosis).
- Morphine (International database) - INN/BAN/JAN names, ATC N02AA01, and pharmacopoeial salt monographs (USP, BP, Ph. Eur., Ph. Int., JP).
- Equianalgesic opioid dosing tables - 10 mg parenteral morphine as the conventional equianalgesic reference, with oral morphine about threefold less potent.
- Prevention of Opioid Overdose - Dose-related overdose risk and CDC/Canadian caution against chronic morphine-equivalent doses above 50-90 mg/day.
What the second pass must settle
- Does an existing Vercy world model already own morphine or its chemical-form distinctions, requiring this registry entry to link to it?
- Which authoritative identity references and analytical criteria should establish morphine identity for each supported material context?
- Which salts, hydrates and content-expression conventions must this entry cover, and where should medicinal-product models take ownership?
- Which current specifications and stability evidence apply to each supported form and intended purpose, including impurity limits and retest criteria?
- Which jurisdictions and institutional settings must the model support, and how will activity permissions and handling references be kept current?